Oxford Biodynamics appoints new CFO

Oxford Biodynamics today announced the appointment of Paul Stockdale as its new chief financial officer.

Stockdale was to join the group from e-Therapeutics on 15 September 2017, where he held the position of financial controller since January 2012. He also worked closely with the CFO and was responsible for internal and external financial reporting.

He would be taking over from Katie Long who was returning to her role within Tessera Investment Management Limited having established and been responsible for OBD's finance function over the previous nine months and during the company's IPO.

Long was due to step down from the board on 30 June 2017 and would support OBD on an interim basis during the transitional period.

Oxford BioDynamics is a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry.

The group's current market capitalisation stands at £120.21m.

It's shares were up 0.18% to 139.00p at 15:11 BST